国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2014年
21期
1618-1620
,共3页
慢性阻塞性肺疾病急性加重期%基质金属蛋白酶-9%基质金属蛋白酶组织抑制剂-1%孟鲁司特钠
慢性阻塞性肺疾病急性加重期%基質金屬蛋白酶-9%基質金屬蛋白酶組織抑製劑-1%孟魯司特鈉
만성조새성폐질병급성가중기%기질금속단백매-9%기질금속단백매조직억제제-1%맹로사특납
Acute exacerbations of chronic obstructive pulmonary disease%Matrix metalloproteinase-9%Tissue inhibitor of metalloproteinases-1%Montelukast sodiumr
目的 通过采用酶联免疫吸附试验(ELISA)法测定中重度慢性阻塞性肺疾病急性加重期(acute exacerbations of chronic obstructive pulmonary disease,AECOPD)患者治疗前、后血清基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)和基质金属蛋白酶组织抑制剂-1(tissue inhibitor of metalloproteinases-1,TIMP-1)水平,观察孟鲁司特钠对中重度AECOPD患者血清MMP-9、TIMP-1水平的影响.方法 选取中重度AECOPD患者63例为研究对象,随机分组:治疗组30例,给予常规治疗+孟鲁司特钠10 mg,1次/d,口服,疗程7～14 d;对照组33例,给予常规治疗,疗程7～14 d.采用双抗体夹心酶联免疫吸附法测定两组血清MMP-9和TIMP-1水平,并对其变化进行分析比较.结果 ①治疗组和对照组治疗前MMP-9水平比较差异无统计学意义,治疗组治疗后MMP-9水平[(22.02±6.34) μg/L]低于对照组治疗后[(26.31±8.23) μg/L](P＜0.05).治疗组和对照组治疗前MMP-9水平分别为[(27.59±7.71) μg/L]、[(27.74±7.96) μg/L]均高于治疗后[(22.02±6.34)tg/L]、[(26.31±8.23) μg/L](P＜0.05).②治疗组和对照组治疗前TIMP-1水平比较差异无统计学意义,治疗组治疗后[(22.23±5.52) μg/L]TIMP-1水平高于对照组治疗后[(17.23±8.23) μg/L](P＜0.05).治疗组和对照组治疗前TIMP-1水平均分别为[(16.34±1.45)μg/L]、[(16.20±2.03) μg/L]低于治疗后[(22.23±5.52) μg/L]、[(17.23±2.45) μg/L](P＜0.05).结论 孟鲁司特钠对中重度AECOPD患者血清MMP-9和TIMP-1水平有影响,推测孟鲁司特钠可减轻中重度AECOPD患者气道炎症并延缓气道重塑.
目的 通過採用酶聯免疫吸附試驗(ELISA)法測定中重度慢性阻塞性肺疾病急性加重期(acute exacerbations of chronic obstructive pulmonary disease,AECOPD)患者治療前、後血清基質金屬蛋白酶-9(matrix metalloproteinase-9,MMP-9)和基質金屬蛋白酶組織抑製劑-1(tissue inhibitor of metalloproteinases-1,TIMP-1)水平,觀察孟魯司特鈉對中重度AECOPD患者血清MMP-9、TIMP-1水平的影響.方法 選取中重度AECOPD患者63例為研究對象,隨機分組:治療組30例,給予常規治療+孟魯司特鈉10 mg,1次/d,口服,療程7～14 d;對照組33例,給予常規治療,療程7～14 d.採用雙抗體夾心酶聯免疫吸附法測定兩組血清MMP-9和TIMP-1水平,併對其變化進行分析比較.結果 ①治療組和對照組治療前MMP-9水平比較差異無統計學意義,治療組治療後MMP-9水平[(22.02±6.34) μg/L]低于對照組治療後[(26.31±8.23) μg/L](P＜0.05).治療組和對照組治療前MMP-9水平分彆為[(27.59±7.71) μg/L]、[(27.74±7.96) μg/L]均高于治療後[(22.02±6.34)tg/L]、[(26.31±8.23) μg/L](P＜0.05).②治療組和對照組治療前TIMP-1水平比較差異無統計學意義,治療組治療後[(22.23±5.52) μg/L]TIMP-1水平高于對照組治療後[(17.23±8.23) μg/L](P＜0.05).治療組和對照組治療前TIMP-1水平均分彆為[(16.34±1.45)μg/L]、[(16.20±2.03) μg/L]低于治療後[(22.23±5.52) μg/L]、[(17.23±2.45) μg/L](P＜0.05).結論 孟魯司特鈉對中重度AECOPD患者血清MMP-9和TIMP-1水平有影響,推測孟魯司特鈉可減輕中重度AECOPD患者氣道炎癥併延緩氣道重塑.
목적 통과채용매련면역흡부시험(ELISA)법측정중중도만성조새성폐질병급성가중기(acute exacerbations of chronic obstructive pulmonary disease,AECOPD)환자치료전、후혈청기질금속단백매-9(matrix metalloproteinase-9,MMP-9)화기질금속단백매조직억제제-1(tissue inhibitor of metalloproteinases-1,TIMP-1)수평,관찰맹로사특납대중중도AECOPD환자혈청MMP-9、TIMP-1수평적영향.방법 선취중중도AECOPD환자63례위연구대상,수궤분조:치료조30례,급여상규치료+맹로사특납10 mg,1차/d,구복,료정7～14 d;대조조33례,급여상규치료,료정7～14 d.채용쌍항체협심매련면역흡부법측정량조혈청MMP-9화TIMP-1수평,병대기변화진행분석비교.결과 ①치료조화대조조치료전MMP-9수평비교차이무통계학의의,치료조치료후MMP-9수평[(22.02±6.34) μg/L]저우대조조치료후[(26.31±8.23) μg/L](P＜0.05).치료조화대조조치료전MMP-9수평분별위[(27.59±7.71) μg/L]、[(27.74±7.96) μg/L]균고우치료후[(22.02±6.34)tg/L]、[(26.31±8.23) μg/L](P＜0.05).②치료조화대조조치료전TIMP-1수평비교차이무통계학의의,치료조치료후[(22.23±5.52) μg/L]TIMP-1수평고우대조조치료후[(17.23±8.23) μg/L](P＜0.05).치료조화대조조치료전TIMP-1수평균분별위[(16.34±1.45)μg/L]、[(16.20±2.03) μg/L]저우치료후[(22.23±5.52) μg/L]、[(17.23±2.45) μg/L](P＜0.05).결론 맹로사특납대중중도AECOPD환자혈청MMP-9화TIMP-1수평유영향,추측맹로사특납가감경중중도AECOPD환자기도염증병연완기도중소.
Objective Serum of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels moderate and severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients before and after treatment were tested using ELISA to observe the effect of montelukast modiumr on serum MMP-9 and TIMP-1 levels.Methods Sixty-three cases mild moderate and severe AECOPD were selected that were randomly divided into 30 cases as treatment group and 33 cases as control group.The treatment group were given conventional therapy plus montelukast sodium (10 mg oral treatment once-daily for 7-14 days).The control group were given conventional therapy for 7-14 days.Serum of MMP-9 and TIMP-1 levels in moderate and severe AECOPD patients before and after treatment were tested using ELISA and compared with its changes.Results ①Before the treatment,the comparison of MMP-9 serum level between the treatment group and control group has no significant difference (P ＞0.05).While the serum level in treatment group [(22.02 ± 6.34)μg/L] is higher than the control group after the treatment [(26.31±8.23) μg/L](P ＜0.05).The serum level in the treatment group [(27.59 ± 7.71) μg/L] and control group [(27.74 ± 7.96) μg/L] is respectively higher than group after the treatment [(22.02 ± 6.34) μg/L],[(26.31 ± 8.23) μg/L] (P ＜0.05).②Serum level of TIMP-1 before the treatment has no significant difference between the treatment group and control group(P ＜ 0.05).Though the serum level after the treatment is different between these two groups [(22.23±5.52) μg/L],[(17.23±8.23) pg/L,respectively](P ＜0.05).The serum level in the treatment group [(16.34±1.45) μtg/L] and control group [(16.20±2.03) μg/L] is respectively higher than group after the treatment [(22.23 ± 5.52) μg/L,(17.23 ± 2.45) pg/L,respectively (P ＜ 0.05).Conclusions Montelukast sodiumr do have an effect on serum level of MMP-9 and TIMP-1 in AECOPD,which seems that montelukast sodiumr may alleviate the inflammation in air flue and delay the airway remodeling.
